News & Updates

Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.

Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.

In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.